0

Granisetron Reduces the Need for Uterotonics but Not Sympathomimetics During Cesarean Delivery

Florian J Raimann, Henrica P Baldauf, Frank Louwen, Lukas Jennewein, Dania Fischer, Kai Zacharowski, Christian F Weber

Int J Gynaecol Obstet. 2019 Jun;145(3):361-366.

PMID: 30932170

Abstract:

Objective:
To assess the effect of a 5-hydroxytryptamine-3 receptor antagonist (granisetron) on the use of sympathomimetic (cafedrine/theodrenaline) and uterotonic (oxytocin) agents after spinal anesthesia during cesarean delivery.
Methods:
A retrospective observational analysis was conducted using intraoperative records (n=240) created at a single hospital in Germany between November 1, 2016, and July 31, 2017. The granisetron group (n=120) had received 3 mg of granisetron immediately before induction of spinal anesthesia. The control group (n=120) had not received granisetron. The primary endpoints were the intraoperative requirements for sympathomimetic and uterotonic agents. The secondary endpoints were parameters of intraprocedural maternal hemodynamic and clinical states.
Results:
More patients in the granisetron group than in the control group received intraoperative cafedrine/theodrenaline (P=0.045), with the cumulative intraoperative dosage also increased in the granisetron group (P=0.016). By contrast, the cumulative intraoperative dose of oxytocin was lower in the granisetron group than in the control group (P<0.001). Decreases in heart rate and mean arterial blood pressure were lower in the granisetron group versus the control group (P=0.015 and P=0.002, respectively).
Conclusion:
Treatment with granisetron immediately before cesarean delivery did not reduce the perioperative requirement for sympathomimetics but did reduce the need for uterotonics. REGISTERED AT CLINICALTRIALS.GOV (NCT03318536).

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
CS31041792 Granisetron Granisetron Price
qrcode